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Background: Inhaled bronchodilators are ﬁrst line drugs in the treatment of chronic
obstructive pulmonary disease (COPD). Tiotropium bromide is a recently introduced long-
acting anticholinergic agent able to reduce dyspnoea and COPD exacerbations and to
improve pulmonary function and quality of life. We designed a study to compare the short-
term efﬁcacy of tiotropium bromide with that of oxitropium bromide in improving
pulmonary function in patients with COPD.
Methods: Eighty patients were randomized either to continue oxitropium 800mcg/day or
to receive tiotropium 18mcg/day. Seventy-six (39 in the tiotropium and 37 in the
oxitropium group) completed the study. Plethysmography was performed at baseline and
after 72 h in all patients. The changes in functional parameters in the two groups were
compared by the Mann–Whitney U-test.
Results: There were no differences between the two groups regarding age (72.5 vs. 74.2
years), male/female ratio (25/14 vs. 23/14) and pulmonary function at baseline. The
changes in spirometric parameters were signiﬁcantly greater in tiotropium- than in
oxitropium-treated patients: mean forced expiratory volume in 1 s (FEV1) increased
signiﬁcantly by 15% vs. 3% (P ¼ 0:017), mean FVC by 10.5% vs. 2.2% (P ¼ 0:044), and FEF
25, 50, and 75 by 34% vs. 14% (Po0.05), 33% vs. 7% (Po0.05), and 50% vs. 6% (Po0.0001),
respectively; mean FRC and RV decreased nonsigniﬁcantly by 7.5% and 10% with tiotropium
vs. 4.3% and 6.5% with oxitropium, respectively.
Conclusion: The replacement of oxitropium with tiotropium signiﬁcantly increases
pulmonary function in patients with COPD. The improvement involves also small airways
that have not been investigated thus far.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
9 02 5513852.
a@fastwebnet.it (C. Incorvaia).
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nergics, are the mainstay of treatment for chronic obstruc-
tive pulmonary disease (COPD).1–3 They are able to improve
symptoms and exercise capacity,4 and to decrease the
frequency of COPD exacerbations.5,6
Tiotropium bromide is a second-generation anticholiner-
gic agent that is structurally related to ipratropium
bromide. Its main distinguishing characteristic is slow
dissociation from Hm1 and Hm3 muscarinic receptors,7
which results in sufﬁciently prolonged pharmacological
activity8 to allow once daily administration. After the ﬁrst
dose, mean time to onset of its bronchodilating effect
is 30min and mean time to peak effect is about 3 h.
Subsequent doses increase efﬁcacy even further until
maximum bronchodilating activity is achieved after 1 week.9
A number of clinical studies have demonstrated the
efﬁcacy of tiotropium in reducing dyspnoea and COPD
exacerbations and in improving quality of life.10–12 More-
over, signiﬁcant effects on pulmonary function have been
reported, namely increase in forced expiratory volume in 1 s
(FEV1) and forced vital capacity (FVC),
13 and decrease in
functional residual capacity (FRC), which indicates that the
drug reduces lung hyperinﬂation.14
The objective of this study was to assess short-term
changes in pulmonary function, including small airways
variables, in patients with COPD on treatment with another
anticholinergic agent, oxitropium bromide, during either
continuation of treatment with oxitropium bromide or
replacement treatment with tiotropium bromide.
Materials and methods
Patients
Eighty patients referred to the Unit of Pulmonary Rehabi-
litation of the ICP Hospital in Milan were included in the
study. To be included, patients had to be in stable
conditions, with no exacerbations for at least 2 months, in
GOLD stage 2–4 according to FEV1 values,
1 and on treatment
with only oxitropium bromide as bronchodilator. Treatment
with other bronchodilators or inhaled corticosteroids was an
exclusion criterion. The patients were randomized either to
continuation of treatment with oxitropium (800mcg daily)
or to replacement of oxitropium with tiotropium (18mcg
daily). In patients maintained on treatment with oxitro-
pium, the inhalation technique was optimized by using
spacer devices, if they had not been already introduced. The
need to inhale the drug every 6 h was stressed. Patients
initiating treatment with tiotropium were instructed to use
the dry powder inhaler device.Table 1 Baseline characteristics of the two treatment groups.
Treatment No. of patients Gender Ag
Oxitropium 37 23 m, 14 f 74
Tiotropium 39 25 m, 14 f 72Pulmonary function
The FEV1, the FVC, the expiratory ﬂows at low volumes (FEF
25, 50, and 75), the FRC, and the residual volume (RV) were
measured by an automated pulmonary function testing
center (6200 Autobox DL, Sensor Medics, Yorba Linda, CA,
USA) in accordance with recognized standards.15 Variables
were measured at inclusion and after 72 h: this interval was
chosen to avoid confounding by pulmonary rehabilitation
procedures.16 The last dose before repeat measurement
was given 3 h before for oxitropium and 1 h before for
tiotropium.
Statistical analysis
The differences in the absolute changes of respiratory
parameters between post- and pre-intervention in tiotro-
pium- and oxitropium-treated patients were analysed by the
Mann–Whitney U-test, setting a P value lower than 0.05 as
signiﬁcant.
Results
Of the 80 patients included, four did not perform the
second plethysmography, three (two in the oxitropium and
one in the tiotropium group) because they withdrew
the informed consent and one (in the oxitropium group)
because family problems made compliance with the
rehabilitation program difﬁcult. Thus, 76 patients (39 in
the tiotropium and 37 in the oxitropium group) were
evaluated for the study. Thirteen patients of the oxitropium
group did not use any spacer device and were instructed to
use it. The baseline characteristics of the two treatment
groups are shown in Table 1: the two groups were well
matched.
The changes in each parameter vs. baseline are reported
in Table 2. The increases in mean FEV1, FVC, and FEF 25, 50,
and 75 were signiﬁcantly higher in patients treated with
tiotropium than in those treated with oxitropium, whereas
the decrease in mean FRC and RV was larger in tiotropium
treated patients but did not reach statistical signiﬁcance.
This is depicted in Fig. 1.
Discussion
A considerable body of evidence collected following the
introduction of tiotropium bromide into clinical practice
makes it a ﬁrst-line drug for the treatment of COPD.9–14
A recent meta-analysis of nine randomized controlled
studies has clearly shown that the drug amelioratese FEV1 (% predicted) FVC (% predicted)
.277.1 49.2716.3 72.6715.3
.576.5 44.3713.3 77.8719.2
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Table 2 Changes in mean values of functional parameters in patients treated with oxitropium and tiotropium.
Parameter Oxitropium Tiotropium
Baseline Post-treatment % difference Baseline Post-treatment % difference
FEV1 9497301 9777299 +3 9217385 10597498 +15
FVC 19177604 19607575 +2.2 19807706 21887826 +10.5
FRC 430871706 412471600 4.3 457771648 423471446 7.5
RV 368971444 345071346 6.5 370471706 333071298 10.1
FEF25 12627905 144271015 +14.3 10897866 146171131 +34.1
FEF50 5417355 5797388 +7 4167292 5527461 +32.6
FEF75 178781 1897110 +6.2 1497110 2247181 +50.3
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Figure 1 Changes in mean values of FEV1, FVC, FRC, and RV (A) and of FEF25, 50, and 75 (B) in patients treated with oxitropium and
tiotropium.
C. Incorvaia et al.478symptoms and related quality of life, reduces the incidence
of disease exacerbations and improves pulmonary function,
as well as increasing exercise capacity.17The improvement in spirometric parameters achieved
with tiotropium was apparent not only as compared to
placebo-treated patients,13,14 but also in subjects treated
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in mean FEV1 in patients treated with tiotropium was
signiﬁcantly higher compared to those treated with the
long-acting b2-agonist salmeterol12 and an improvement in
FEV1 value was observed even in patients regularly treated
with the other b2-agonist formoterol.18 The superiority in
respect of the ﬁrst-generation anticholinergic ipratropium is
made unmistakable by the meta-analysis,17 while to our
knowledge no comparison with oxitropium is available. In
respect to ipratropium, oxitropium has a longer pharmaco-
logical action which enables twice a-day dosing and is as
effective as ipratropium in terms of the bronchodilating
activity.19
In the present study we compared the short-term effects
on pulmonary function parameters of the introduction of
tiotropium in patients with COPD, randomizing the subjects
either to continue treatment with oxitropium—after opti-
mizing the dosage and the inhaling technique—or to replace
it with tiotropium. In oxitropium-treated subjects small
increases in FEV1, FVC, and FEF 25, 50, and 75 were found,
as well as small decreases in FRC and RV, which were likely
to be due to the optimization of treatment. The changes
were greater in tiotropium-treated patients: mean FEV1
increased signiﬁcantly by 15% vs. 3% in oxitropium-treated
patients, mean FVC by 10.5% vs. 2.2%, FEF 25 by 34% vs. 14%,
FEF 50 by 33% vs. 7%, and FEF 75 by 50% vs. 6%. By contrast,
mean FRC decreased nonsigniﬁcantly by 7.5% with tiotro-
pium vs. 4.3% with oxitropium, and RV decreased nonsigni-
ﬁcantly by 10% vs. 6.5%.
This degree of improvement is not unexpected, because
even higher values were reported in placebo-controlled
studies. For example, the ﬁrst dose of tiotropium increased
mean FEV1 by 16% and mean FVC by 17% in patients with
stable COPD.13 In a long-term study the addition of
tiotropium to other standard drug treatments was able to
increase mean FEV1 up to 22% and mean FVC up to 12%.
10 In
our study, also the difference in FEF 25, 50, and 75 between
tiotropium- and oxitropium-treated patients was signiﬁcant:
tiotropium produced larger increase in these parameters,
which are related to small airways calibre, with a P
valueo0.05 for FEF 25 and FEF 50, ando0.0001 for FEF 75.
To the best of our knowledge, previous evaluations on the
effects of tiotropium on small airways are not available. The
improvement we observed, particularly for FEF75, which
was the most marked among the spirometric measurements,
is likely to be linked to the efﬁciency of the dry powder
inhaler device in delivering the drug into the airways and to
the interaction with muscarinic receptors in the smooth
muscle of small airways.20 The importance of this portion of
the respiratory tract was recently claimed by a study, in
which bioptic evidence disclosed a close correlation
between severity of small airway obstruction and clinical
severity of COPD.21 Consequently, future investigation on
the efﬁcacy of drug treatment should take into account the
changes occurring in small airway calibre. The dilation of
small airways is expected to reduce the air trapping and
then the hyperinﬂation parameters. Previous studies re-
ported that treatment with tiotropium achieves a signiﬁcant
decrease in lung hyperinﬂation, as measured by the
inspiratory capacity (IC), an event usually associated with
improvement in exertional dyspnoea.14,22 In the present
study the decrease in hyperinﬂation induced by tiotropium,as measured by FRC and RV, did not achieve statistical
signiﬁcance; this may have been due to the short period of
observation—3 days. This short period was planned to avoid
confounding effects by the pulmonary rehabilitation proto-
col, but may have been not long enough to reach maximum
improvement, which was achieved with tiotropium in other
studies after 42 days14 and 28 days.22 A recent study showed
that also shorter durations of treatment with tiotropium,
starting from 1 week, are sufﬁcient to signiﬁcantly improve
IC but not RV,23 and this offers support to our ﬁndings.
In conclusion, the results of our study conﬁrm the greater
efﬁcacy of tiotropium in respect of previous generation
anticholinergic agents in the treatment of COPD, and
suggest that the drug possesses a signiﬁcant effect on small
airways thus far not investigated.References
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